KPRX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
Cost of Revenue
0
0
0
0
0
Gross Profit
Operating Expenses
2.2M
-11.8%
2.5M
-65.7%
7.3M
+820.2%
794.4K
-66.8%
2.4M
R&D
2.1M
-2.2%
2.1M
-27.5%
2.9M
+7.3%
2.7M
+5.4%
2.6M
SG&A
1.4M
-14.2%
1.6M
+10.6%
1.5M
+1.0%
1.4M
+6.6%
1.4M
Operating Income
-2213771
+11.8%
-2510195
+65.7%
-7310086
-820.2%
-794437
+66.8%
-2396196
EBITDA
-2203030
+11.9%
-2499632
+6.6%
-2675578
-241.3%
-783885
+67.2%
-2392773
Net Income
-2079010
+14.0%
-2417984
+62.9%
-6516521
-24409.9%
26.8K
+101.2%
-2152459
EPS (Basic)
$-0.34
+41.4%
$-0.58
+62.8%
$-1.56
-15700.0%
$0.01
+101.9%
$-0.54
EPS (Diluted)
$-0.34
+41.4%
$-0.58
+65.7%
$-1.69
-17000.0%
$0.01
+101.9%
$-0.54
Shares (Diluted)
6.2M
+48.0%
4.2M
+8.5%
3.8M
-11.8%
4.4M
+9.3%
4.0M
Kiora Pharmaceuticals (KPRX) — Financials